Aaron Weaver

Aaron Weaver is a Senior Partner at Apeiron Investments, a private investment group founded by Christian Angermayer focused on the “next human agenda” through investing and building companies to shape a better future for humanity. Apeiron operates as a stage agnostic and diversified investor with it’s main focus towards technology and biotechnology. Aaron is a board member at the clinical stage longevity biotech Rejuveron Life Sciences and previously held the first investor director seat at the NYSE listed AI biotech, Alto Neuroscience. Aaron was also a investment director at Frontier Acquisition Corp, a NASDAQ listed SPAC focused on longevity with Peter Attia and David Sinclair. Aaron was also an early team member at the mental health biotech atai Life Sciences. Aaron has also been an assistant referee and regulatory consultant to the Ultimate Fighting Championship (UFC) more than a decade.

He is a Chartered Financial Analyst (CFA) and a registered solicitor in the United Kingdom. Prior to Apeiron, Aaron was an investment banker at Credit Suisse in London within the Capital Markets Solutions team and previous to that, a solicitor at Allen & Overy LLP, London from 2007 – 2013. He holds a Masters of Law from the Queensland University of Technology and a Bachelor of Business Administration from the University of Queensland.